옵션 체인은 다양한 행사가격과 만기일에 대한 Longevity Health Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Longevity Health Holdings에 대한 시장 심리를 평가합니다..

Longevity Health Holdings (NASDAQ:XAGEW) 주식, 옵션 체인

Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.

Longevity Health Holdings, Inc. - Warrant

Longevity Health Holdings Inc

With federal pressure mounting and fintech innovations accelerating, the credit score system landlords used to know isn't the same anymore.&nbsp;
In 2025, three big updates are changing how credit scores show if someone can be trusted to pay rent. Landlords need to keep up with these changes because they affect what info gets looked at and how well scores predict if a tenant will be reliable. This all matters when deciding who to rent to and how to manage risks.
<h2 class="wp-block-heading">What is a Credit Score Algorithm? How Does It Work?</h2>
<h3 class="wp-block-heading">Definition of Credit Score Algorithm</h3>
A credit score algorithm is basically a set of rules or a formula that helps lenders or landlords figure out how likely someone is to pay back money on time. It looks at your financial habits and gives you a number (a credit score) that shows how reliable you are with money.
<h3 class="wp-block-heading">How Does It Work? Key Factors Credit Score Algorithms Consider</h3>
These algorithms watch your money habits to guess how trustworthy you'll be in the future. Before, they mostly checked if you paid bills on time, how much debt you have, and how much of your credit you're using.
These days, these algorithms are smarter and look at a lot more information. Besides the usual stuff, they might also check things like:&nbsp;
<ul class="wp-block-list">
<li>History of paying rent,&nbsp;</li>
<li>Utility bills,&nbsp;</li>
<li>Subscriptions,&nbsp;</li>
<li>(and even) Bank transactions.</li>
</ul>
<h3 class="wp-block-heading">Credit Score Ranges</h3>
These expanded data points can be sorted into credit score ranges.&nbsp;
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Credit Score Range</td>
<td>Level of Creditworthiness</td>
</tr>
<tr>
<td>Below 580</td>
<td>Poor</td>
</tr>
<tr>
<td>580 – 669</td>
<td>Fair</td>
</tr>
<tr>
<td>670 – 739</td>
<td>Good</td>
</tr>
<tr>
<td>740 – 799</td>
<td>Very good</td>
</tr>
<tr>
<td>800 – 850</td>
<td>Excellent</td>
</tr>
</tbody>
</table>
</figure>
A credit score of 840, for example, indicates exceptional financial behavior, typically someone with a long history of on-time payments, low credit utilization, and stable income.
<h2 class="wp-block-heading">The 4 Rs of Credit Scoring: A New Framework for Evaluating Tenants</h2>
The credit score algorithm in 2025 is built on four foundational pillars, which are called the 4Rs of credit scoring, including: Risk, Response, Revenue, and Retention. Each one looks at a different part of a person's financial story to help predict how they'll handle renting a home.
<ul class="wp-block-list">
<li>Risk: Measures the chance a tenant might miss payments, considering not just if but how often, how serious, and how long financial problems last. It also looks at the context to avoid unfairly rejecting good tenants because of old or isolated issues.</li>
<li>Response: Looks at how tenants handle financial challenges: Do they ignore problems or try to fix them quickly? This spots who is responsible and resilient versus disorganized or reactive.</li>
<li>Revenue: Checks how steady and reliable a <a href="https://www.leaserunner.com/blog/how-to-verify-tenant-income">tenant's income</a> is by analyzing banking and employment data</li>
<li>Retention: Estimates how likely a tenant is to stay for the full lease by examining past moves, lease lengths, and payment behavior.</li>
</ul>
How does this change the tenant evaluation? In previous years, landlords might reject someone just because they had a late payment years ago. But now, with these new tools, they can see if the tenant bounced back quickly and has steady income. This way, landlords can give a chance to responsible renters who had some temporary problems but are reliable now.
<h2 class="wp-block-heading">3 Key Regulatory Shifts in 2025 That Are Changing Credit Reporting (What Landlords Must Know)</h2>
In 2025, the Trump administration enacted several reforms aimed at modernizing credit assessment and reducing what it called "unfair penalties" for consumers. As these changes roll out, landlords must understand how they alter the accuracy and reliability of the credit score algorithm used in tenant screening.
<h3 class="wp-block-heading">1. Remove Medical Debt from Credit Reports</h3>
One of the most significant changes: medical debt is now excluded from credit reports altogether. The Biden administration argued that medical expenses are often unpredictable, involuntary, and not a true reflection of financial behavior. In 2025, all major credit bureaus are required to eliminate medical collections from scoring models.
Credit scores will better reflect a tenant's real financial habits. Applicants who might have been flagged before because of medical debts now get a fairer shake.
<h3 class="wp-block-heading">2. Introduction of New Credit Scoring Models</h3>
In response to regulatory pressure for more inclusive and transparent credit assessments, the Consumer Financial Protection Bureau (CFPB) approved new credit scoring systems. These new models focus more on what's happening now. They look closely at things like recent payments, rent history, and even subscription bills.
These changes are changing the way credit scores work. The old FICO scores are being updated or replaced by newer versions like FICO 10T and VantageScore 5.0. These newer scores give landlords a better idea of how a tenant is really doing financially today. If landlords stick to old reports, they might miss out on responsible renters who didn't have perfect credit in the past but have been paying rent and bills on time lately.
<h3 class="wp-block-heading">3. AI and Alternative Data Transform Credit Assessments</h3>
Another rule from the Biden era allowed credit companies to use a lot more types of data in their credit checks, along with more legal freedom to try out AI.&nbsp;
This policy shift accelerated the adoption of algorithms that use bank transaction histories, utility payments, gig economy earnings, and even behavioral analytics to assess creditworthiness. The AI involved mainly includes machine learning systems that automatically analyze all this varied data to spot patterns and trends that traditional methods might miss.
The AI here uses smart computer programs that look at all this different info to find patterns that traditional methods might miss. Because of this, people who used to be &#8220;unscorable&#8221; now have detailed credit profiles. This shift opens the door for landlords to consider renters who might not have a long credit history but are still financially responsible.
To sum up, in 2025, credit reports no longer include medical debt. New scoring models now focus on recent payments like rent and bills. AI and alternative data help more renters, especially those without long credit histories, get fair credit evaluations.
<h2 class="wp-block-heading">How Landlords Can Use Credit Scores Effectively in Tenant Screening</h2>
With the recent changes in how credit scores are calculated, landlords can no longer simply label a score as good or bad. To truly understand a potential tenant, landlords should consider credit scores as one piece of a more comprehensive tenant evaluation. 
For example, a score in the mid-600s may have previously signaled caution, but if that score now reflects strong rental history and stable income, the risk may actually be low.
Best practices for landlords in 2025 include:
<ol class="wp-block-list">
<li>Find out which credit scoring model is being used (like FICO or VantageScore) and whether it uses traditional or alternative data. Some models focus more on recent payments and rent, while others look at long-term credit history. Some even use AI to include things like gig work or unusual income.</li>
<li>Reviewing payment histories, not just scores &#8211; especially rent and utility payments: Paying rent on time regularly often says more than the credit score alone.</li>
<li>Using credit scores alongside income verification and landlord references: Combining the credit score with these other data points gives a more accurate risk profile.</li>
<li>Working with screening providers that include AI or machine learning insights for a fuller picture: These tools pull in more info like bank activity, subscription payments, and job trends to better understand how someone manages their money.</li>
</ol>
<h2 class="wp-block-heading">Conclusion</h2>
In short, the credit scoring algorithm has changed over the years, and tenant screening must change with it. Landlords who stay informed, understand the data behind the score, and align with modern models will be better positioned to reduce risk and improve retention. A smarter approach to screening starts with understanding what's changed.

Opinion

Personal Finance

Real Estate

Can You Trust You Tenant To Pay Rent? 3 Big Changes In Credit Score Algorithm Landlords Should Not Ignore In 2025

<a href="https://www.globenewswire.com/Tracker?data=eByy-YPo9LgknwfqYokUc3HXhmktVBLopAc7r6DYOtqVbH-GRzXzCB13-GxGp3xAadt6M8gRMzTrpyOQsUK7wDqlnkxOzGwaveLakZ3sp0o=">Telos Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>), a leading provider of cyber, cloud and enterprise security solutions for the world's most security-conscious organizations, today announced that it was awarded the Defense Information System Agency (DISA) Organizational Messaging Branch contract in support of the DISA Organizational Messaging Service (OMS) Telos Automated Message Handling System (AMHS) product sustainment and support services. The contract is valued at $14 million over five years.

News

Telos Bags $14M DISA Organizational Messaging Branch Contract In Support Of DISA OMS Telos AMHS Product Sustainment And Support Services

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended.
In addition to the $7.0 million upfront payment, HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. Furthermore, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

Biotech

Contracts

General

HCWB

HCW Biologics And WY Biotech Finalize Binding Agreement Following Due Diligence On Technology Transfer For Immunotherapy Molecule HCW11-006, With HCWB Receiving $7M Upfront License Fee And Eligibility For Milestone Payments And Royalties While Retaining Option To Recapture North And Central American Rights Post-Phase 1 Trial

TOP Ships Inc. (the "Company" or "TOP Ships") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#NYSE">TOPS</a>), an international owner and operator of modern, fuel-efficient "ECO" tanker vessels, announced today that it intends to effect a spin-off of two of its Suezmax tanker vessels.
Rubico Inc. ("Rubico"), currently a subsidiary of TOP Ships, would become an independent publicly-traded company listed on the Nasdaq Capital Market as a result of the planned spin-off. The initial assets of Rubico will be the M/T Eco Malibu and M/T Eco West Coast, each a modern, high specification, scrubber-fitted and fuel-efficient 157,000 dwt Suezmax tanker.
As part of the spin-off transaction, TOP Ships intends to distribute 100% of the common shares of Rubico to its securityholders of record as of June 16, 2025. The distribution of common shares of Rubico is expected to be made on or around June 30, 2025. Following the spin-off, there are expected to be no overlapping board members or executive officers between Rubico and TOP Ships.
In the spin-off distribution, TOP Ships intends to distribute 100% of the common shares of Rubico pro rata to the common shareholders of TOP Ships and to all holders of outstanding common stock purchase warrants of TOP Ships on an as-exercised basis.

Dividends

TOPS

TOP Ships Announces Planned Spin-Off Of 2 Fuel-Efficient Suezmax Tankers Into Newly Public Nasdaq Company Rubico Inc., With Share Distribution To TOP Ships Securityholders Expected By June 30, 2025

MAMO

Massimo Group Announces Strategic Nearshoring Initiative To Transition To Nearshoring Manufacturing Model

Approximately 500 million redemptions are processed through GFT Rewards annually
Datavault AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>), a leader in AI-driven data experience, valuation and monetization, today announced a strategic licensing agreement with GFT Rewards to deploy ADIO&#xAE;-enabled, Web 3 mobile rewards across major distribution channels from airports and retail chains to movie exhibitors, college campuses and Ride-Hailing networks.
GFT Rewards is a pioneer in web 3 promotions and rewards, transforming how shoppers discover and redeem offers across mass diverse distribution channels from grocery stores, stadiums and movie theatres, to college campuses and Ride-Hailing Networks. By partnering with major brands like T-Mobile, Kroger, Toshiba, Marvel and others, GFT Rewards reinvented reward creation, distribution, redemption and reimbursements, making it frictionless and profitable for retailers to hyper-scale, target and personalize their rewards and loyalty platforms, while making it easier and much more abundant for consumers to engage and reap the benefits.
In its latest initiative, GFT Rewards has teamed up with Datavault AI and ADIO&#xAE; to set a new standard for programmatic reward distribution, from coupons and rebates to web 3, tokenized loyalty incentives. Leveraging ADIO's patented inaudible-tone technology, this collaboration enables retailers and brands to deliver cash-redeemable or tokenized loyalty offers directly to consumers' mobile devices. Under the terms of the agreement, Datavault AI will receive a fee for every reward redemption managed and redeemed through GFT's platform with ADIO.
Datavault AI has licensed its proprietary audio-based ADIO&#xAE; solution to GFT Rewards to trigger secure mobile reward redemptions through ultrasonic tones embedded in advertisements and digital media. These rewards are instantly redeemed at the point of sale, offering real-time incentives to shoppers. GFT Rewards will utilize its GFT Cash App to execute revenue-share payments to partners with AI analytics and redemption reporting built into its dashboard.
"Retailers are experiencing a growing demand for frictionless, instant savings and rewards tied to digital ads and proximity triggers," said Jonas Hudson, Co-CEO of GFT Rewards. "This partnership combines our financial infrastructure and marketplace with Datavault AI's ultra-targeted, tone-based ad delivery system to enable the next generation in Web 3 rewards, sales and ROI for brands, distributors and IP."
The global mobile coupon market continues its rapid ascent. Valued at $603.3 billion in 2023, the market is projected to reach $1.6 trillion by 2030, reflecting accelerating digital adoption and evolving shopping habits among global consumers. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcapitaloneshopping.com%2Fresearch%2Fcoupon-statistics%2F&amp;esheet=54264966&amp;newsitemid=20250604125554&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcapitaloneshopping.com%2Fresearch%2Fcoupon-statistics%2F&amp;index=1&amp;md5=57e9f23f9170ad202a617bf70ccfb08d">https://capitaloneshopping.com/research/coupon-statistics/</a>)
"These numbers show that while coupons are ubiquitous, their impact lies in how strategically they are delivered and redeemed," said Jonas Hudson, Co-CEO of GFT Rewards. "Brands that optimize their loyalty and incentive strategies—particularly via mobile—stand to gain significant consumer engagement and revenue lift."
As shoppers increasingly expect instant, low-friction experiences, retailers and brands are moving toward technologies that enable real-time engagement, automated delivery and seamless integration within everyday media. This shift is fueling demand for promotions that can be activated passively, in the moment and in response to media exposure—precisely the type of delivery model ADIO&#xAE; supports.
Unlike legacy solutions reliant on barcodes or QR codes, ADIO&#xAE; operates via encrypted, high-frequency tones that can be layered into any audio environment—streaming services, television broadcasts, retail PA systems or social video. The technology enables fully passive activation, with coupons appearing as notifications or digital wallet entries the moment the tone is detected.
"By integrating ADIO&#xAE; technology into the cash ecosystem of GFT, we're giving advertisers a way to turn impressions into transactions instantly," said Nathaniel Bradley, CEO of Datavault AI. "ADIO&#xAE; is an ideal solution for this kind of performance marketing, and we expect significant velocity in adoption as retailers and brands look to reduce friction in the promotional funnel. GFT's system is already rolling out across select banners with national reach, and we anticipate this model becoming a standard for performance-based in-store media."
The agreement expands Datavault AI's channel access in key sectors, including consumer packaged goods (CPG), fast-moving consumer goods (FMCG) and high-volume grocery retail, all of which are facing increased pressure to demonstrate ROI on every promotional dollar. The ADIO&#xAE; + GFT Rewards software delivers SKU-level tracking, geo-anchored performance reporting and immediate economic attribution, creating a new standard for coupon campaign accountability.

DVLT

Datavault AI Enters Strategic Licensing Agreement With GFT Rewards To Deploy ADIO-Enabled, Web 3 Mobile Rewards Across Major Distribution Channels

Citigroup analyst Xiaopo Wei initiates coverage on Chagee Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHA#NASDAQ">CHA</a>) with a Buy rating and announces Price Target of $43.7.

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Chagee Holdings with Buy Rating, Announces Price Target of $43.7

BKTI

BK Technologies To Join Russell 2000 And Russell 3000 Indexes

Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) ("Nixxy" or the "Company"), an AI-powered data and communications infrastructure company, today announced the successful acquisition of the Leadnova.ai platform assets from the NexGenAI suite of companies. Nixxy also reported that it generated approximately $5.2 million in unaudited gross revenue for the month of May 2025 up from approximately $1.4 million in April 2025.

NIXX

Nixxy Acquires Leadnova.ai Platform Assets From NexGenAI Suite Of Companies; Nixxy Generates Gross Revenues Of About $5.2M In May 2025

GlobalFoundries Announces $16B Investment To Reshore Essential Chip Manufacturing And Accelerate AI Growth

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D").
The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.

BDRX

Biodexa Pharmaceuticals Announces First Patient Dosed In Phase 2 Investigator-Initiated Trial Of Tolimidone For Type 1 Diabetes At University Of Alberta, Evaluating Insulin And Glucose Markers Across Three Dose Groups with Potential For Study Expansion

Dollar Tree Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)&nbsp;stock is <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower during the premarket</a>&nbsp;after its first-quarter 2025 earnings report.
Net sales increased 11.3% to $4.6 billion, beating the consensus of $4.53 billion and the management guidance of $4.5 billion—$4.6 billion.
Same-store net sales increased 5.4%, driven by a 2.5% increase in traffic and a 2.8% <a target="_blank" href="https://www.benzinga.com/trading-ideas/previews/25/06/45754249/dollar-tree-q1-earnings-preview-can-the-discount-retailer-beat-and-raise-like-peer-dollar-general" rel="noreferrer noopener">increase in average ticket</a>, beating the management guidance growth of 3% – 5%.
6.4% consumables <a target="_blank" href="https://corporate.dollartree.com/_assets/_fb720ee9222d1724ca4693e29c9ff376/dollartreeinfo/db/857/11067/pdf/Dollar+Tree+Inc.+Q1+2025+IR+Supplemental+-+FINAL+AS+PUBLISHED.pdf" rel="noreferrer noopener">comp</a> and 4.6% discretionary comp – highest discretionary comp growth since Q4 2022.
On Wednesday, Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21, better than management expectation of $1.10 – $1.25.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44677660/the-new-bull-case-for-dollar-tree-raise-prices-boost-margins-blame-tariffs" rel="noreferrer noopener">Dollar Tree Surges Nearly 8% After Citi Upgrade: Analysts Say Tariffs Could Boost Margins, Not Hurt Them</a>
Gross profit increased 11.7% to $1.6 billion. The gross margin expanded 20 basis points to 35.6%, driven primarily by lower freight, improved mark-on, and lower occupancy costs due to sales leverage, partially offset by increased distribution, <a href="https://www.benzinga.com/pressreleases/25/06/b45766244/dollar-tree-inc-reports-results-for-the-first-quarter-fiscal-2025">shrink, and markdown costs</a>.
Adjusted operating income increased 1.4% to $387.8 million, and adjusted operating margin contracted 80 basis points to 8.4%.
In March, the company <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">agreed to sell</a> the Family Dollar business to Brigade and Macellum for $1.007 billion. Net proceeds are estimated to total approximately $800 million. Additionally, Dollar Tree expects the economic impact of tax benefits from losses on the sale to be approximately $350 million. The deal is expected to close in the second quarter of fiscal 2025.
Fiscal Outlook
Dollar Tree reaffirms <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">fiscal year 2025 sales&nbsp;guidance</a> of $18.5 billion—$19.11 billion versus a consensus of $18.95 billion, based on comparable store net sales growth of 3% to 5%.
The company said its outlook assumes the current tariff level remains in effect for the balance of the fiscal year and that it will be able to mitigate most of the incremental margin pressure from higher tariffs and other input costs.
The company raised its adjusted earnings guidance from $5.00-$5.50 per share to $5.15-$5.65 per share compared to analysts estimate of $5.21.
As Dollar Tree will bear the full year of the costs to support Family Dollar but only expects to receive offsetting reimbursement income in the second half of the year, the company&#8217;s full-year earnings will be negatively impacted by approximately 30 cents to 35 cents per share, with that impact concentrated in the first two quarters of the fiscal year.
Second Quarter 2025 Outlook
Given trends and expectations for the balance of the quarter, Dollar Tree expects Q2 comparable net sales growth to be towards the higher end of its full-year outlook range of 3% to 5%.
Over the balance of fiscal 2025, the company expects to mitigate the earnings impact of the cost pressures it faces, including higher tariffs.
In the near term, it expects to see some earnings volatility based on the timing of the various inputs and outputs to the company&#8217;s financial results.
The company expects that the second-quarter adjusted EPS from continuing operations could be down as much as 45% to 50% year-over-year before re-accelerating in the third and fourth quarters to meet its full-year earnings outlook.
On Tuesday, the company&#8217;s rival Dollar General Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) stock closed around 16% higher at $112.57 after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45746307/dollar-general-boosts-annual-outlook-despite-ongoing-tariff-uncertainty" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
Dollar Tree updated its expectations for the year, primarily to reflect its outperformance in the first quarter and the tariff uncertainty. It now expects fiscal year 2025 sales growth of approximately 3.7% to 4.7%, compared to its previous expectation of approximately 3.4% to 4.4%.
Same-store sales growth is expected to be approximately 1.5% to 2.5%, compared to its previous expectation of approximately 1.2% to 2.2%
Price Action: DLTR shares traded higher by 3.10% at $69.22 in premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?</a></li>
</ul>

Earnings

Retail Sales

Movers

Trading Ideas

DLTR

Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raises the price target from $83 to $129.

Upgrades

BPMC

Citigroup Upgrades Blueprint Medicines to Neutral, Raises Price Target to $129

<ul>
<li>Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market</li>
<li>Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development</li>
<li>Cost-efficient approach&nbsp;enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value</li>
<li>Synergistic combination therapies&nbsp;under evaluation could redefine treatment standards in veterinary and human applications</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit" or the "Company") today announced that it has entered into a joint development agreement with Manoira Corporation ("Manoira"), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit's AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational data across human and veterinary applications.
Manoira will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to generate preclinical data that will better inform Conduit's human clinical programs. Notably, early animal studies conducted by AstraZeneca suggest that glucokinase activators may have therapeutic potential in osteoarthritis1. In addition, Manoira plans to evaluate a novel combination of its patented CBDA co-crystal with AZD1656 and AZD5658 for the treatment for osteoarthritis in animals.
This cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications. The partnership not only enhances Conduit's core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market, creating a dual-track value proposition for its shareholders. The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings. Additionally, Manoira will evaluate AZD5658 for veterinary applications, expanding the utility of Conduit's glucokinase activator portfolio and supporting cross-species insight generation.

Conduit Pharmaceuticals And Manoira Announce Strategic Joint Development Agreement To Evaluate Glucokinase Activators AZD1656 And AZD5658 For Veterinary Use

LIPO

Lipella Pharmaceuticals Re-Signs Manufacturing Collaboration Agreement With Cook MyoSite For LP-310 Clinical Development

Management

HNRG

Hallador Energy Company Appoints Todd Telesz As CFO

PAX's award-winning portable dry herb cannabis vaporizers now more broadly available through Greenlane's distribution platform

GNLN

Greenlane Renews Distribution Agreement With PAX

Gadolinium-160 is a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapies. &nbsp;
- Supply agreement is for four years' supply of enriched Gd-160, commencing in 2026, with an expected minimum contract value of $1 million per annum.
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has recently entered into a supply agreement with Isotopia Molecular Imaging Ltd. related to the supply of enriched Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This agreement addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumours, and other malignancies.
Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The supply agreement is for four years' supply, commencing in 2026, with an expected minimum contract value of $1 million per annum.
The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years.
Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms."
Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US."
Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumour-seeking molecules.
It is expected that Gd-160 will be enriched using the Company's Quantum Enrichment process, a novel laser-based approach to enriching isotopes. The Gd-160 plant will be part of a large Quantum plant that the Company is in the process of designing and constructing. Additional isotopes that are expected to be enriched in this large-scale laser facility include Nickel-64, Zinc-68, Ytterbium-176, Barium-137, Ytterbium-171 and Lithium 6/7.
This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. The Company is in discussions with other customers who require Gd-160 and expects to sign additional orders during 2025

ASPI

ASP Isotopes And Isotopia Enters Supply Agreement For Gadolinium-160 To Help Accelerate Terbium-161 Production For Advanced Cancer Therapies With Expected Minimum Contract Value Of $1M Per Year

PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), owner of brands such as Tommy Hilfiger and Calvin Klein, will release earnings results for the first quarter, after the closing<a href="https://www.benzinga.com/quote/PVH/earnings"> bell on Wednesday, June 4</a>.
Analysts expect the New York-based company to report quarterly earnings at $2.25 per share, down from $2.45 per share in the year-ago period. PVH projects to report quarterly revenue at $1.93 billion, compared to $1.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 30, Needham analyst Tom Nikic initiated coverage on PVH with a Buy rating. He gave the company a price target of $115.
With the recent buzz around PVH, some investors may be eyeing potential gains from the company's dividends too. Currently, PVH offers an annual dividend yield of 0.18%. That&#8217;s a quarterly dividend amount of 4 cents per share (15 cents a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $3,301,600 or around 40,000 shares. For a more modest $100 per month or $1,200 per year, you would need $660,320 or around 8,000 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.15 in this case). So, $6,000 / $0.15 = 40,000 ($500 per month), and $1,200 / $0.15 = 8,000 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
PVH Price Action: Shares of PVH gained 0.5% to close at $82.54 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Fell</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From PVH Stock Ahead Of Q1 Earnings

Citigroup analyst Ryan Levine downgrades Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) from Buy to Neutral and raises the price target from $232 to $318.

Comments

Longevity Health Holdings

Longevity Health Holdings (XAGEW) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌